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ABSTRACT Growing evidence suggests that tran-
scription factor signal transducer and activator of tran-
scription (Stat) 3 may play an important regulatory role
during inflammation. However, the function of Stat3 in
acute lung injury (ALI) is largely unknown. In the
current study, by using an adenoviral vector expressing
a dominant-negative Stat3 isoform (Ad-Stat3-EVA), we
determined the role of Stat3 in IgG immune complex
(IC)-induced inflammatory responses and injury in the
lung from C57BL/6J mice. We show that IgG IC-
induced DNA binding activity of Stat3 in the lung was
significantly inhibited by Stat3-EVA. We demonstrate
that both lung vascular permeability (albumin leak) and
lung myeloperoxidase accumulation in the Ad-Stat-EVA
treated mice were substantially reduced when com-
pared with values in mice receiving control virus (Ad-
GFP) during the injury. Furthermore, intratracheal
administration of Ad-Stat3-EVA caused significant de-
creases in the contents of neutrophils, inflammatory
cytokines (TNF- and IL-6), chemokines [keratinocyte
cell-derived chemokine, macrophage inflammatory pro-
tein (MIP)-1, and MIP-1], and complement compo-
nent C5a in bronchoalveolar lavage fluids. Using Stat3-
specific small interfering RNA, we show that knocking
down Stat3 expression in alveolar macrophages (MH-S
cells) significantly reduced the production of proin-
flammatory mediators on IgG IC stimulation. These
data suggest that Stat3 plays an essential role in the
pathogenesis of IgG IC-induced ALI by mediating the
acute inflammatory responses in the lung and alveolar
macrophages.—Tang, H., Yan, C., Cao, J., Sarma, J. V.,
Haura, E. B., Wu, M., Gao, H. An essential role for
Stat3 in regulating IgG immune complex-induced pul-
monary inflammation. FASEB J. 25, 4292–4300 (2011).
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Signal transducer and activator of transcription
(Stat) 3 belongs to a family of 7 different transcription
factors that play crucial roles in cytokine signaling. The
function of Stat3 has been extensively studied in cell
culture systems as well as in vivo. While genetic deletion of
Stat3 causes early embryonic lethality, studies from tissue
or cell-specific deletion of the Stat3 gene have suggested
that Stat3 may play an important role during inflamma-
tion (1). Stat3 is expressed in the lung. Its function in lung
during inflammation has recently attracted attention. For
example, employing both knockout and transgenic ap-
proaches, expression of Stat3 in respiratory epithelial cells
has been indicated as a key regulator in maintenance of
surfactant homeostasis and lung function during hyper-
oxia-induced acute lung injury (ALI; refs. 2–4). Further-
more, Stat3 has been shown to play a crucial cytoprotec-
tive role in epithelial cell survival and maintenance of
alveolar structures during the early phases of pulmonary
adenoviral infection (5). Recently, Stat3 was reported to
play a critical role in regulating surfactant lipid synthesis
in both normal and LPS-injured lungs (6). Moreover, in
Escherichia coli pneumonia, Stat3 has a beneficial effect by
limiting infection and lung injury (7). Stat3 activation has
also been reported in other ALI models, such as hemor-
rhagic shock, gastric acid aspiration, and acute pancreati-
tis (8, 9). Furthermore, a recent study using small mole-
cule inhibitors linked Stat3 inhibition to the attenuated
lung injury induced by LPS (10). These observations
suggest that Stat3 may be a common pathway for mediat-
ing ALI. Thus, the role of Stat3 during lung inflam-
mation is likely to be complex and begs further
investigation.
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The IgG immune complex (IC) model in the rodent lung
has been extensively employed to investigate the molecular
mechanisms of acute lung inflammatory injury (11). In this
model, the intra-alveolar deposition of IgG IC activates
alveolar macrophages, which results in robust formation of
the early response cytokines including TNF-. The proin-
flammatory cytokines induce expression of chemokines and
adhesion molecules on leukocytes and endothelial/epithe-
lial cells, all of which together induce a strong proinflamma-
tory cascade that causes an acute damage in the lung.
Growing evidence indicates that regulation of inflammatory-
associated gene expression in the lung are mediated by a
highly intricate network of transcription factors, especially
NF-B (11, 12). Interestingly, our recent studies in the IgG
IC-induced lung injury model have shown that Stat3 is
activated in both alveolar macrophages and whole lung
extracts following IgG IC deposition (13). However, the
biological relevance for these inductions is not known. In the
current study, we determine the functional role of Stat3 in
IgG IC-induced ALI. Using an adenoviral vector expressing a
dominant-negative Stat3 isoform (Ad-Stat3-EVA) in vivo and
a specific siRNA for Stat3 in vitro, we show that Stat3 plays an
essential role in the pathogenesis of IgG IC-induced ALI by
mediating acute inflammatory responses in the lung and
alveolar macrophages.
MATERIALS AND METHODS
Animals and cell culture
In all experiments, specific pathogen-free male C57BL/6
mice obtained from the Jackson Laboratory (Bar Harbor, ME,
USA) were used at the age of 8–12 wk (weighing 20–30 g).
FcR-deficient mice were obtained from Taconic (German-
town, NY, USA). All procedures involving mice were ap-
proved by the Animal Care and Use Committee of Harvard
Medical School. MH-S cells were obtained from American
Type Culture Collection (Manassas, VA, USA). Cells were
cultured in RPMI 1640 medium supplemented with 10 mM
HEPES, 2 mM l-glutamine, 100 U/ml streptomycin,100
U/ml penicillin, and 10% (v/v) FBS.
Intratracheal administration of adenovirus
The construction of adenoviral vector for Stat3-EVA expres-
sion was described previously (14). Recombinant adenovi-
ruses were purified by BD Adeno-X virus purification kit (BD
Clontech, Palo Alto, CA, USA) and stored in aliquots at
80°C. The viral stocks were titered using Adeno-X rapid
titer kit (BD Clontech). Unless otherwise indicated, 30 l of
adenovirus (5108 PFU of Ad-Stat3-EVA or Ad-GFP control
adenovirus) was administered to mice via an intratracheal
injection, using a Hamilton syringe with a sterile 30-gauge
needle. After 72 h, lungs were harvested for the analysis of
Stat3 DNA binding activity, or mice were used for IgG
IC-induced lung injury.
Experimental model of IgG IC-induced lung injury
Mice were anesthetized with intraperitoneal ketamine (100
mg/kg body weight; Fort Dodge Animal Health, Fort Dodge, IA,
USA) and xylazine (12.5 mg/kg body weight; Ben Venue
Laboratories, Benford, OH, USA) for sedation. The trachea was
surgically exposed by a midline incision, and 120 g of rabbit
anti-BSA IgG (MP Biomedicals, Solon, OH, USA) in 40 l of
PBS was administered by tracheal puncture with a 30-gauge
needle. The incision was closed by surgical clips, and 2 mg of
bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO,
USA) in a volume of 200 l was injected intravenously immedi-
ately thereafter. Control mice received anti-BSA or PBS intratra-
cheally in the absence of an intravenous infusion of BSA.
Assessment of Stat3 activation by EMSA
Nuclear extracts of whole lung tissues were prepared, as
described previously (15). Briefly, frozen lungs were homog-
enized in solution A containing 0.6% (v/v) Nonidet P-40, 150
mM NaCl, 10 mM HEPES (pH 7.9), 1 mM EDTA, 0.5 mM
PMSF, and protease inhibitor cocktail (complete protease
inhibitors; Roche, Indianapolis, IN, USA). Proteins were
extracted from nuclei by incubation at 4°C with vigorous
vortexing in solution B containing 420 mM NaCl, 20 mM
HEPES (pH 7.9), 1.2 mM MgCl2, 0.2 mM EDTA, 25% (v/v)
glycerol, 0.5 mM DTT, 0.5 mM PMSF, and protease inhibitor
cocktail (Roche). Protein concentrations were determined by
Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA) using
BSA as a reference standard. The EMSA probes were double-
stranded oligonucleotides containing the Stat3 consensus
sequence (5-GATCCTTCTGGGAATTCCTAGATC-3; Santa
Cruz Biotechnology, Santa Cruz, CA, USA). The probe was
end labeled with [-32P]ATP (3000 Ci/mmol at 10 mCi/ml;
Amersham Biosciences, part of GE Healthcare Biosciences, Piscat-
away, NJ, USA). DNA-binding reactions were performed at room
temperature as described previously (15). Samples were electro-
phoresed through 5.5% polyacrylamide gels in 1TBE at 160 V for
2 h, dried under vacuum, and exposed to X-ray film.
Bronchoalveolar lavage (BAL) fluid analysis
BAL fluids were harvested at different time periods after IgG
IC deposition for total leukocyte count, differential cell
counts, and quantification of chemokine/cytokine produc-
tion by ELISAs. For differential cell counts, the slides were
quantified for neutrophils, macrophages, and lymphocytes by
counting a total of 200 cells/slide in randomly selected
high-powered fields (400). BAL levels of TNF-, IL-6,
keratinocyte cell-derived chemokine (KC), macrophage in-
flammatory protein; (MIP)-1, MIP-1, and C5a were deter-
mined using ELISA kits (R&D Systems, Minneapolis, MN,
USA) according to the instructions of the manufacturer.
Myeloperoxidase (MPO) assay
Lungs were perfused via the right ventricle with 10 ml of
sterile PBS, snap-frozen, and stored at 80°C. To measure
MPO activity, whole lungs were homogenized and sonicated
in 50 mM potassium phosphate buffer containing 0.5%
hexadecyltrimethylammonium bromide and 5 mM EDTA.
After centrifugation at 12,000 g for 10 min at 4°C, 10 l of
supernatant fluids containing MPO was incubated with 250 l
of 100 mM potassium phosphate buffer containing 5 g/ml
hydrogen peroxide and 167 g/ml o-dianisidine dihydrochlo-
ride (Sigma-Aldrich). The enzymatic activity was determined
spectrophotometrically by measuring the kinetics in absor-
bance at 450 nm over 3 min using a 96-well plate reader
(DTX880 Multimode Detector; Beckman, Brea, CA, USA; ref. 16).
Determination of albumin content in BAL fluids
Mouse albumin levels in BAL fluid were measured using a
mouse albumin ELISA kit purchased from Bethyl Laborato-
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ries (Montgomery, TX, USA). The detection limit for this
ELISA was 7 ng/ml.
Morphological assessment of lung injury
At 4 h after IgG IC deposition, lungs were fixed by intratra-
cheal instillation of 0.8 ml of buffered formalin (10%; Fisher
Scientific, Fairlawn, NJ, USA) and then further fixed in 10%
buffered formalin solution for histological examination to
evaluate the lung injury by tissue sectioning and staining with
hematoxylin and eosin (H&E).
Stat3-siRNA transfection
MH-S cells were transfected with 600 nM control siRNA or
Stat3 siRNA (Santa Cruz Biotechnology) by using Amaxa
Nucleofector II device (Lonza Group, Basel, Switzerland),
according to the manufacturer’s instructions. At 24 h after
transfection, the cells were incubated with 100 g/ml IgG IC
for different time periods. Total RNA was then isolated with
the Trizol reagent (Invitrogen, Carlsbad, CA, USA) for RT-
PCR analysis of Stat3 m RNA expression. Supernatants were
collected for ELISA assays.
Detection of Stat3 expression by RT-PCR
RT-PCR was performed with 2 g of total RNA using the
2-step RT-PCR system (Fisher Scientific, Pittsburgh, PA,
USA). The following primers were used for PCR: Stat3,
forward primer, 5-CCCCCGGGCACCTTCCTACT-3, and re-
verse primer, 5-GGGCTCAGCACCTTCACCGTTATT-3; and
GAPDH, forward primer, 5-GCCTCGTCTCATAGACAAGATG-3,
and reverse primer, 5-CAGTAGACTCCACGACATAC-3.
Statistical analysis
All values are expressed as means 	 se. Values of P 
 0.05 were
considered significant. Data sets were analyzed using Student’s t test
or 1-way ANOVA, with individual group means being compared
with the Student-Newman-Keuls multiple comparison test.
RESULTS
Ad-Stat3-EVA inhibited DNA binding activity of Stat3
in IgG IC- injured lungs
Our previous work in rats had shown that Stat3 was
activated in the whole lung during IgG IC-induced lung
injury (13). We evaluated the time course of Stat3
activation during IgG IC-induced lung injury in mice by
EMSA. As shown in Fig. 1A, at time 0, low levels of
constitutive Stat3 in lung nuclear extracts were ob-
served. Stat3 activation was evident by 1 h and became
strongest at 4 and 8 h. Subsequently, Stat3 binding
activity dramatically decreased at 24 h after IC deposi-
tion. Three classes of activating FcRs have been re-
ported (FcRI, FcRIII, and FcRIV), which share a
common FcR-chain that is critical for receptor activa-
tion (17). Using FcR-chain-knockout mice, we then
determined that activating FcRs are involved in Stat3
activation in the inflamed lungs (Fig. 1B). To elucidate
the significance of Stat3 activation in IgG IC-injured
lungs, we employed an adenoviral vector expressing a
dominant-negative Stat3 isoform (Ad-Stat3-EVA) for
our study. Stat3-EVA has 2 mutations in the DNA
binding site of Stat3, which prevents its binding to DNA
but has no effect on tyrosine phosphorylation or
dimerization (14). Thus, it can form dimers with en-
dogenous Stat3; however, when expressed in cells,
Stat3-EVA attenuates the ability of Stat3 to bind to its
binding sites. To determine whether Ad-Stat3-EVA can
inhibit Stat3 DNA binding activity in the lungs, we used
a dose of 5.0  108 PFU for intratracheal virus admin-
istration. This dose has been shown to trigger no
intrapulmonary inflammatory response (18). As shown
in Fig. 1C, no Stat3 activation was detected in control
lungs (intratracheally injected with control virus, Ad-
Figure 1. Effects of Stat3-EVA overexpression on FcR-dependent Stat3 activation in IgG IC-injured lungs. A) Nuclear extracts
from whole lungs harvested at different time points after IgG IC deposition were subjected to EMSA assay for Stat3 DNA binding
activity. B) Nuclear extracts from wild-type and FcR / mouse lungs 4 h after IgG IC deposition were subjected to EMSA assay
for Stat3 DNA binding activity. C) Mice received Ad-GFP or Ad-Stat3-EVA 72 h before the lung injury. Nuclear extracts from
whole lungs harvested 4 h after IgG IC deposition were subjected to EMSA assay for Stat3 DNA binding activity.
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GFP, in the absence of IgG IC deposition). A substan-
tially increased DNA binding activity for Stat3 was
observed in the IgG IC-injured lungs. However, IgG
IC-induced DNA binding activity for Stat3 in the lung
was inhibited by Stat3-EVA overexpression. Using dif-
ferent in vitro and in vivo approaches, we have recently
excluded the possibility that any of the effects following
IgG IC stimulation of cells or deposition in the lungs
are based on LPS contamination of the reagents (19).
Thus, the activation of Stat3 in the IgG IC-injured lungs
was mediated by a genuine agonist effect.
Effects of Ad-Stat3-EVA-mediated Stat3 inhibition on
IgG IC-induced lung injury and MPO activity in lung
homogenate
After demonstrating the ability of Ad-Stat3-EVA to
inhibit the DNA binding activity of Stat3 in the lung, we
determined whether Ad-Stat3-EVA can affect IgG IC-
induced lung injury. At 72 h after intratracheal admin-
istration of Ad-GFP or Ad-Stat3-EVA, IgG IC-mediated
lung injury was induced. We examined whether Stat3-
EVA overexpression changes the pulmonary vascular
permeability after IgG IC deposition by measuring
albumin level in the BAL fluids. As shown in Fig. 2A,
IgG IC deposition (4 h) caused a significant increase in
albumin level in BAL fluids from the mice receiving
Ad-GFP. Notably, albumin content in the BAL fluids
from the IgG IC-injured mice receiving Ad-Stat3-EVA
was significantly reduced (P
0.01).
We further examined MPO activity, which is a marker
for the lung neutrophil burden. As shown in Fig. 2B,
MPO activity in lung homogenate significantly in-
creased in injured mice compared with noninjured
mice (P
0.01). As with albumin leakage, lung MPO
content in mice receiving Ad-Stat3-EVA was signifi-
cantly lower when compared with values in mice receiv-
ing Ad-GFP during the injury (P
0.05).
To further determine whether overexpression of
Stat3-EVA reduces IgG IC-induced lung injury, histo-
logical analyses were performed. As shown in Fig. 3A,
C, mice receiving Ad-GFP or Ad-stat3-EVA alone
exhibited normal lung architecture with no evidence
of inflammation. In the presence of IgG IC, mice
receiving Ad-GFP exhibited lung hemorrhage,
edema, fibrin deposition, and accumulation of neu-
trophils (Fig. 3B). In contrast, all of these features
were mitigated 4 h after IgG IC deposition in mice
receiving Ad-Stat3-EVA (Fig. 3D). These data to-
gether indicate that inhibiting Stat3 DNA binding
activity provides protection against the development
of pulmonary capillary permeability, increased neu-
trophil recruitment, and lung injury after IgG IC
deposition in the lung.
Effects of Ad-Stat3-EVA-mediated Stat3 inhibition on
leukocyte counts in BAL fluid from IgG IC-injured lungs
BAL fluids were harvested from IgG IC-injured or
noninjured lungs at different time periods. As shown in
Fig. 4A, the total number of white blood cells in the
BAL fluids significantly increased at all time periods (4,
8, and 24 h) examined in mice with injury when
compared with control animals. The major cells in BAL
fluids from noninjured lungs were mononuclear mac-
rophages and lymphocytes (Fig. 4). In injured lungs,
the majority of cells were neutrophils (Fig. 4). Notably,
there was a decrease level of neutrophil number in
IgG IC-injured mice receiving Ad-Stat3-EVA when
compared with the mice receiving Ad-GFP (Fig. 4B).
Moreover, there was not a significant change (in-
crease) in the number of macrophages and lympho-
cytes in BAL fluids from the IgG IC-injured mice
receiving Ad-Stat3-EVA as compared with those re-
ceiving Ad-GFP (Fig. 4C).
Figure 2. Effects of Stat3-EVA overexpression on IgG IC-induced lung injury. Lung vascular permeability and neutrophil
accumulation in mice receiving Ad-Stat3-EVA were compared with mice receiving Ad-GFP in the presence (IgG-IC) and absence
(Ctrl) of IgG IC deposition. A) Mouse albumin levels in whole lungs were measured as an index for vascular leakage. B) MPO
activity in whole lungs was used as an index of neutrophil accumulation in the lungs. Data are represented as means 	 se; n 
4–6. *P 
 0.05.
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Effects of Ad-Stat3-EVA-mediated Stat3 inhibition on
cytokine/chemokine levels in BAL fluid from IgG
IC-injured lungs
We evaluated the effects of overexpression of Stat3-EVA
on levels of proinflammatory cytokines/chemokines in
BAL fluids at different time periods after IgG IC-
deposition. As shown in Figs. 5 and 6, virus infection
alone, in the absence of IC deposition, did not induce
an increase in the levels of proinflammatory mediators.
In IgG IC-injured lungs infected with Ad-GFP control
virus, there were progressive increases in BAL proin-
Figure 3. Effects of Stat3-EVA overexpression on lung histology during IgG IC-induced lung injury. Sections from lungs
harvested 72 h after virus administration with or without IgG IC deposition (4 h) were stained with H&E. Shown are
representative sections for each condition. Original view: 200. A) Lung section from mice receiving Ad-GFP absent any other
stimulus. B) Lung section from mice receiving Ad-GFP together with IgG IC deposition. C) Lung section from mice receiving
Ad-Stat3-EVA absent any other stimulus. D) Lung section from mice receiving Ad-Stat3-EVA together with IgG IC deposition.
Figure 4. Effects of Stat3-EVA overexpression on leukocyte counts in BAL fluid from IgG IC-injured lungs. Leukocytes were
quantitated in BAL fluids 4, 8, and 24 h after onset of IgG IC-induced lung injury in mice treated with either Ad-GFP or
Ad-Stat3-EVA. Leukocytes were also quantitated in BAL fluids from control mice that received BSA intratracheally together
with either Ad-STAT3-EVA or Ad-GFP, but in the absence of intravenously administered BSA. Total numbers of leukocytes (A),
neutrophils (B), and macrophages/lymphocytes (C) are shown. Results are expressed as means 	 se; n  3 for control and n 
5 for other time points. *P 
 0.05, **P 
 0.01.
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flammatory cytokines/chemokines, peaking at 4–8 h,
followed by a decline at 24 h. Moreover, Ad-Stat3-EVA
administration led to decreased levels of TNF-, IL-6,
KC, MIP-1, and MIP-1 in IgG IC-injured lungs at
all time points examined when compared with mice
that were administrated Ad-GFP virus (Figs. 5 and 6),
suggesting that Stat3 may play a critical roles for
cytokine and chemokine production in IgG IC-in-
jured lungs.
Effects of Ad-Stat3-EVA-mediated Stat3 inhibition on
C5a level in BAL fluid from IgG IC-injured lungs
Previous studies have demonstrated that C5a plays an
essential role for the full production of TNF-, lung
injury, and neutrophil accumulation in IgG IC induced
lung injury (20, 21). We thus investigated whether over-
expression of Stat3-EVA regulates the IgG IC-induced C5a
production in the BAL fluids. As shown in Fig. 7, Ad-Stat3-
EVA alone, in the absence of IC deposition, did not
induce an increase in the C5a level. In IgG IC-injured
lung with Ad-GFP present, C5a level in BAL fluids was
significantly elevated (Fig. 7). Notably, Ad-Stat3-EVA ad-
ministration led to a significantly decreased level of C5a in
BAL fluids at all time points examined, when compared
with mice that received Ad-GFP.
Stat3-siRNA inhibited cytokine/chemokine secretion
from macrophages when incubated with IgG IC
Our previous study suggested that Stat3 activation in the
IgG IC-injured lung was macrophage dependent (13).
Therefore, we sought to determine the effects of Stat3
deficiency on the secretion of proinflammatory mediators
from IgG-IC-stimulated alveolar macrophages. We first
showed that Stat3 expression was efficiently down-regu-
lated by siRNA specific for Stat3, in MH-S, an alveolar
macrophage cell line, by RT-PCR (Fig. 8A). We next
showed that secretions of TNF-, IL-6, MIP-1, and
MIP-1 were all significantly induced from IgG IC-stimu-
lated MH-S cells. Moreover, on IgG IC treatment, silenc-
ing Stat3 led to a significant decrease in IgG IC-induced
secretion of TNF-, IL-6, MIP-1, and MIP-1 from MH-S
cells at all time points when compared with control
Figure 5. Effects of Stat3-EVA overexpression on BAL contents of TNF- (A) and IL-6 (B). Mice received Ad-STAT3-EVA or
Ad-GFP 72 h before lung injury. BAL fluids were obtained 4, 8, and 24 h after onset of IgG IC-induced lung injury, and analyzed
by ELISAs. Controls received BSA intratracheally together with either Ad-STAT3-EVA or Ad-GFP but in the absence of
intravenously administered BSA. Data are represented as means 	 se; n  3 for control and n  5 for other time points. *P 

0.05; ***P 
 0.001.
Figure 6. Effects of Stat3-EVA overexpression on BAL contents of KC (A), MIP-1 (B), and MIP-1 (C). Mice received
Ad-STAT3-EVA or Ad-GFP 72 h before lung injury. BAL fluids were obtained 4, 8, and 24 h after onset of IgG IC-induced lung
injury and analyzed by ELISAs. Controls received BSA intratracheally together with either Ad-STAT3-EVA or Ad-GFP, but in
the absence of intravenously administered BSA. Data are represented as mean 	 se; n  3 for control and n  5 for other time
points. *P 
 0.05; **P 
 0.01.
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siRNA-treated cells (Fig. 8B–E). C5a can be generated
from IC-stimulated macrophages (22). We thus examined
the effect of Stat3 deficiency on the C5a secretion from
IgG-IC-stimulated alveolar macrophages. As shown in Fig.
8F, IgG IC-stimulated C5a production from MH-S cells
was significantly reduced when Stat3 expression was
down-regulated by siRNA.
DISCUSSION
The pathogenesis of lung injury in response to IgG IC
deposition is initiated by the production of early response
cytokines such as TNF- and the complement activation
product C5a, resulting in induction of proinflammatory
mediators including CXC and CC chemokines, and up-
regulation of vascular adhesion molecules, followed by
neutrophil migration into the interstitial and alveolar
compartments. All these events constitute a strong proin-
flammatory cascade. Several transcription factors, such as
NF-B, AP-1, and CCAAT/enhancer-binding proteins, are
activated following IgG IC stimulation and have been
suggested to be involved in IC-associated inflammatory
responses (13, 23–25). However, these studies are either
indirect or correlative. Our previous studies in the IgG
IC-induced lung injury model have shown that Stat3 is
activated in both alveolar macrophages and whole lung
extracts following IgG IC deposition (13). In the current
study, we show that pretreatment with Ad-Stat3-EVA, an
adenoviral vector expressing a dominant-negative Stat3
isoform, significantly inhibits IgG IC-induced lung injury
as defined by reduced albumin leakage into lung, MPO
content, and histology change in the lung, suggesting that
Stat3 is a key regulator of IgG IC-induced inflammatory
responses in the lung.
Neutrophil transmigration into the alveolar compart-
ment and lung interstitium plays a key role in the devel-
opment of ALI. There is evidence from this study that
Stat3 appears to be an important regulator in neutrophil
recruitment into the lung since inhibition of Stat3 DNA
Figure 7. Effects of Stat3-EVA overexpression on C5a content
in BAL fluid. Mice received Ad-STAT3-EVA or Ad-GFP 72 h
before lung injury. BAL fluids were obtained 4, 8, and 24 h
after onset of IgG IC-induced lung injury, and analyzed by
ELISA for C5a content. Controls received BSA intratrache-
ally together with either Ad-STAT3-EVA or Ad-GFP but in the
absence of intravenously administered BSA. Data are repre-
sented as means 	 se; n  3 for control and n  5 for other
time points. *P 
 0.05; **P 
 0.01; ***P 
 0.001.
Figure 8. Effects of Stat3 silencing on the production of inflammatory mediators in IgG IC-stimulated MH-S cells. A) MH-S cells
were transiently transfected with control siRNA or Stat3-specific siRNA. At 24 h after transfection, the cells were harvested for
RNA isolation, and RT-PCR was performed by using primers for Stat3 and GAPDH, respectively. B–F) MH-S cells were transiently
transfected with control siRNA or Stat3 siRNA. 24 h later, the cells were incubated with 100 g /ml IgG IC for the indicated time
periods. Levels of TNF- (B), IL-6 (C), MIP-1 (D), MIP-1 (E), and C5a (F) in the supernatants were assayed by ELISA. Data
are represented as means 	 se; n  4. *P 
 0.05; **P 
 0.01; ***P 
 0.001.
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binding activity by Ad-Stat3-EVA results in a significant
decrease of neutrophils in BAL fluids. However, the
molecular mechanisms by which Stat3 regulates neutro-
phil migrating into IgG IC-injured lungs are not clear.
One possible mechanism is that of the modulation of
inflammatory cytokines. Both TNF- and IL-6 are inflam-
matory cytokines that play an important role in the
development of ALI by inducing the expression of adhe-
sive interactions between endothelial cells and leukocytes
(21). However, when we compared the expression of
intercellular adhesion molecule (ICAM)-1 and vascular
cell adhesion molecule (VCAM)-1 in Ad-GFP-treated and
Ad-Stat3-EVA-treated lungs in the presence of IgG IC
deposition, we found that Ad-Stat3-EVA treatment has no
significant effect on the ICAM-1 and VCAM-1 expression
as compared with Ad-GFP treatment (data not shown).
These results suggest that Ad-Stat3-EVA might affect
neutrophil adhesion to the lung vascular endothelium
and/or their subsequent transmigration by modulating
alternative adhesion pathways independent of ICAM-1
and VCAM-1. Supporting this observation, Crockett et al.
(26) reported that in a cecal ligation-puncture-induced
sepsis model, gene deletion of P-selectin and ICAM-1 does
not inhibit neutrophil infiltration into peritoneal cavity.
Another possible mechanism of Stat3 involvement in
neutrophil infiltration is its regulation on chemokine
production. Both CXC and CC chemokines are involved
in IgG IC-induced lung injury (11). CXC chemokines
(MIP-2 and KC) play a pivotal role by directly chemoat-
tracting neutrophils along a chemotactic gradient into the
alveolar compartment and lung interstitium (27). CC
chemokines (MIP-1 and MIP-1) seem to function as
autocrine stimulators of alveolar macrophages, priming
them to respond to inflammatory stimuli with enhanced
production of proinflammatory cytokines such as TNF-
(28, 29). Our current finding that intratracheal adminis-
tration of Ad-Stat3-EVA caused significant decreases in the
contents of KC, MIP-1, and MIP-1 supports the above
hypothesis. Interestingly, using a murine model with
conditional Stat3 deletion in bone marrow, Nguyen-Jack-
son et al. (30) recently demonstrated that Stat3 controls
the neutrophil migratory response to CXCR2 ligands
(MIP-2 and KC) by inducing CXCR2 expression and via
modulation of CXCR2 signal transduction. Taken to-
gether, these data suggest that Stat3 mediates neutrophil
infiltration into the lungs by regulating chemokine pro-
duction and chemokine signaling. Interestingly, although
we found that Ad-Stat3-EVA could also lead to a decrease
of BAL MIP-2 production, the reduction is not significant
(data not shown). Furthermore, Chouchakova et al. (31)
showed that FcRIII-mediated production of TNF- in-
duces IC alveolitis independently of MIP-2 and KC gener-
ation. Therefore, it would be interesting to investigate
how and the exact molecular mechanisms whereby MIP-2
and KC regulate IgG IC-induced lung inflammatory re-
sponses.
Probably, the most interesting finding in this study is
that with inhibition of Stat3 DNA binding activity, there
was a reduction in the level of the neutrophil chemotactic
peptide C5a. Compelling evidence showed that C5a is
required for the IgG IC-induced inflammatory responses
in the lung (11, 32). Both C5-deficient mice and in vivo
blockade of C5a showed a significant decrease in vascular
permeability and sharply diminished neutrophil accumu-
lation (21, 33). The protective effects of anti-C5a were
related to its ability to suppress lung macrophage produc-
tion of TNF- (21, 33). Furthermore, C5a plays a critical
role in regulating the expression of the inhibitory/activat-
ing FcR II/III receptor pair (20, 34, 35). The molecular
mechanism whereby Stat3 regulates C5a production re-
mains to be investigated. Interestingly, it has been dem-
onstrated that Stat3 is involved in the IL-6-induced up-
regulation of CCAAT/enhancer-binding protein  and 
gene promoters (32). Furthermore, in the CCAAT/en-
hancer-binding protein -deficient mice, induction of
complement 3 (C3) was totally impaired (36). Thus, it is
tempting to speculate that Stat3 may induce C3/C5
production through CCAAT/enhancer-binding protein-
mediated pathways.
Alveolar macrophages play a major role in IgG IC-
induced lung injury (11, 29). Our previous studies (13)
have shown that Stat3 activation in alveolar macrophages
in vivo occurs before Stat3 activation in whole lung tissues
following IgG IC deposition. Furthermore, IgG IC-in-
duced Stat3 activation is significantly reduced by deple-
tion of alveolar macrophages in the lung (13). It has also
been demonstrated that C5a can be generated by IC-
stimulated macrophages (22). In our current study, we
show that knocking down Stat3 expression in alveolar
macrophage cells significantly reduced the levels of
TNF-, IL-6, MIP-1, and MIP-1 as well as C5a on IgG IC
stimulation. These data suggest that Stat3 is involved in
the production of proinflammatory mediators from alve-
olar macrophages, which initiate the early responses in
lung following IgG IC deposition.
In summary, our studies provide evidence that Stat3
plays a significant role in the pathogenesis of IgG IC-
induced ALI. Furthermore, our data suggest that Stat3 is
an important regulator of C5a production during IC
responses. Although Stat3 activation has been reported in
several acute lung diseases, little is known about the
functional role of Stat3 in the lung and the molecular
mechanisms exerted by Stat3 to regulate acute lung
inflammatory responses. Furthermore, there is no clear
understanding of exactly how Stat3 activation is regulated
in the lung. The net effect of Stat3 activation in various
acute lung diseases may be dependent on under what
disease condition and when and in what cell type Stat3 has
been induced. Thus, identification of Stat3-regulated
downstream mediators (including cytokines/chemokines
and C5a shown in the current study) will lead to a better
understanding how Stat3 regulates acute lung inflamma-
tory responses. This knowledge may help identify new
targets for therapeutic intervention in lung diseases.
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